| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8491932 | CALLIDITAS | Compositions for the oral delivery of corticosteroids |
May, 2029
(5 years from now) | |
| US11896719 | CALLIDITAS | Pharmaceutical compositions |
Jan, 2043
(18 years from now) | |
Tarpeyo is owned by Calliditas.
Tarpeyo contains Budesonide.
Tarpeyo has a total of 2 drug patents out of which 0 drug patents have expired.
Tarpeyo was authorised for market use on 15 December, 2021.
Tarpeyo is available in capsule, delayed release;oral dosage forms.
Tarpeyo can be used as reduction in loss of kidney function in adults with primary immunoglobulin a nephropathy (igan) who are at risk of disease progression, reduction in loss of kidney function and reduction of proteinuria in adults with primary immunoglobulin a nephropathy (igan) who are at risk of disease progression, by release of budesonide from the formulation.
The generics of Tarpeyo are possible to be released after 23 January, 2043.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-389) | Dec 15, 2028 |
| Orphan Drug Exclusivity(ODE-464) | Dec 20, 2030 |
| New Product(NP) | Dec 15, 2024 |
Drugs and Companies using BUDESONIDE ingredient
Market Authorisation Date: 15 December, 2021
Treatment: Reduction in loss of kidney function in adults with primary immunoglobulin a nephropathy (igan) who are at risk of disease progression; Reduction in loss of kidney function and reduction of proteinuri...
Dosage: CAPSULE, DELAYED RELEASE;ORAL
TARPEYO family patents
